Xvivo Perfusion AB
STO:XVIVO
P/FCFE
Price to FCFE
Price to Free Cash Flow To Equity (P/FCFE) ratio is a valuation multiple that compares a company’s market capitalization to the amount of free cash flow available for equity shareholders. This metric is very similar to the P/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.
Market Cap | P/FCFE | ||||
---|---|---|---|---|---|
SE |
Xvivo Perfusion AB
STO:XVIVO
|
13.6B SEK | 225.9 | ||
CH |
Alcon AG
SIX:ALC
|
39.9B CHF | 83 | ||
JP |
Hoya Corp
TSE:7741
|
6.7T JPY | 41 | ||
DK |
Coloplast A/S
CSE:COLO B
|
182.3B DKK | 70.2 | ||
US |
Align Technology Inc
NASDAQ:ALGN
|
19.3B USD | 31.7 | ||
US |
Cooper Companies Inc
NYSE:COO
|
17.9B USD | 76.8 | ||
CN |
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
59.7B CNY | 52.8 | ||
UK |
ConvaTec Group PLC
LSE:CTEC
|
5.1B GBP | 38.3 | ||
KR |
H
|
HLB Inc
KOSDAQ:028300
|
8T KRW | -91.9 | |
CH |
Ypsomed Holding AG
SIX:YPSN
|
5.2B CHF | -614.7 | ||
US |
DENTSPLY SIRONA Inc
NASDAQ:XRAY
|
5.8B USD | 26.2 |
P/FCFE Forward Multiples
Forward P/FCFE multiple is a version of the P/FCFE ratio that uses forecasted free cash flow to equity for the P/FCFE calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to equity forecasts for 1, 2, and 3 years ahead, respectively.